PharmaCyte Biotech Granted FDA Pre-IND Meeting for Pancreatic Cancer Therapy

LAGUNA HILLS, Calif., Nov. 29, 2016, PMCB, (GLOBE NEWSWIRE) PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that a Pre-Investigational New Drug (Pre-IND) meeting with the Center for Biologics Evaluation and Research (CBER) of the U.S. Food and Drug Administration (FDA) has been granted by the FDA. During the meeting with representatives from CBER, they will respond to PharmaCyte’s previously
http://bit.ly/2gfSGjs